Addex stock tanks after lead drug flops in Phase II epilepsy trial
Addex and J&J co-developed the allosteric modulator therapy, which failed to meet the primary endpoint in a Phase II epilepsy trial.
Addex and J&J co-developed the allosteric modulator therapy, which failed to meet the primary endpoint in a Phase II epilepsy trial.
The observational study will assess the clinical and workflow benefits of using Hyperfine’s Swoop system in detecting amyloid abnormalities in Alzheimer’s patients.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Acarix starts clinical workflow study for its AI-powered cardiac diagnostic
Cleerly touts new data for AI cardiovascular software
Moderna’s Phase III Covid-19 vaccine trial meets primary endpoints
Gedeon Richter adopts TransPerfect’s trial management solutions